Susquehanna Fundamental Investments LLC Makes New Investment in Merck & Co., Inc. $MRK

Key Points

• Susquehanna Fundamental Investments acquired 89,259 Merck shares during the second quarter, valued at approximately $11.47 million. Institutional investors collectively own 76.07% of the company.
• Merck reported quarterly revenue of $16.61 billion, up 5.1% year over year, and exceeded analysts’ earnings expectations. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $147.60.
• Merck declared a quarterly dividend of $0.85 per share, equivalent to a 2.3% annualized yield, while company insiders sold 228,238 shares worth nearly $30 million during the last quarter.

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 89,259 shares of the company's stock, valued at approximately $11,470,000.

A number of other large investors also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $25,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Graney & King LLC lifted its holdings in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 0.0%

NYSE MRK opened at $148.30 on Monday. The stock has a 50 day moving average price of $131.78 and a 200-day moving average price of $122.45. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a market capitalization of $365.88 billion, a P/E ratio of 118.64, a P/E/G ratio of 6.22 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter in the previous year, the business posted $2.13 earnings per share. Merck & Co., Inc.'s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares of the company's stock, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last quarter. Company insiders own 0.17% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MRK shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Guggenheim boosted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Argus upped their target price on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. UBS Group raised their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average target price of $147.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source